Trandolapril : pharmacokinetics of single oral doses in healthy male volunteers

The pharmacokinetics and dose proportionality of trandolapril, a new angiotensin-converting enzyme (ACE) inhibitor, were investigated in 12 healthy male volunteers in a four-way randomized crossover study over the therapeutic dose range, 0.5-4 mg. Trandolapril is rapidly absorbed, with a single elimination half-life (t 1/2 ) of 0.72 h, irrespective of dose. Peak plasma levels (C max ) occurred at 0.5 h and were proportional to the dose, as was the area under the plasma concentration-time curve (AUC)